Cancer Genetics Expands Its Industry-Leading Immuno-Oncology Panel, Complete::IO™, to be the Most Comprehensive for Immune ...
January 17 2018 - 7:30AM
- Simultaneously Assesses 27 Unique
Immune Markers
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision
medicine for oncology through molecular markers and diagnostics,
today announced the expansion of its immuno-oncology (IO) panel,
Complete::IO™, to include five new IO markers. This brings the
total number of markers it simultaneously detects to 27, making
Complete::IO™ the most comprehensive flow-cytometry-based biomarker
panel in the industry, with a 24-hour turn around time.
Since its launch in April 2017, Complete::IO has quickly gained
commercial traction and has already been included in notable
immunotherapy trials including studies of CAR-T therapies and
checkpoint inhibitors. Complete::IO™ is a multi-marker panel
enabling comprehensive characterization of the immune repertoire of
cancer patients, including circulating immune cell populations and
the tumor microenvironment. It plays a unique role in identifying
ideal patient populations for specific IO therapies and addresses
the unmet need to monitor and stratify patient populations during
clinical trials. The panel also assures that patients are monitored
for safety and toxicity throughout the trial. The increased number
of markers allows for the identification of rare and challenging
subsets of immune cells.
Besides the commonly studied subsets, central memory, effector,
effector memory cells, naïve CD4+ and CD8+ T cells, T-regs, B-regs,
NK, and plasmacytoid dendritic cells, Complete::IO™ is now able to
power highly accurate immunophenotyping and the measurement of the
frequency of myeloid-derived suppressor cells (MDSCs), as well as
those that express PD-1, PD-L1, or PD-L2.
The presence and frequency of MDSCs, which inhibit anti-tumor
immune response, in the blood of cancer patients, might represent a
novel and accessible biomarker to monitor clinical outcome and
response to therapy. In addition, targeting MDSCs to increase the
efficacy of immunotherapeutics appears to be a clinically promising
strategy, and is being actively evaluated in clinical trials.
According to industry reports, there are over 2,500 active clinical
trials globally related to IO therapies.
“Complete::IO™ analyzes dynamic changes across immune cell
populations, and with this latest expansion, includes additional
biomarkers that have emerged as important to immuno-oncology,” said
Rita Shaknovich, Chief Medical Officer of CGI. “Complete::IO has
the unique ability to determine precise details of anti-tumor
immunity for each patient. Complete::IO™ effectively enables
informed therapeutic decisions and assessment of potential
toxicities of IO therapies in both hematological malignancies and
solid tumors.”
The addition of PD-1, PD-L1 and PD-L2 to the panel is in concert
with recent studies associating the expression of these markers by
tumor cells and/or immune cells in the tumor microenvironment with
clinical efficacy of IO therapies. Flow cytometry as compared to
other methods has the advantage of simultaneously measuring the
expression of PD-1 and its ligands PD-L1 and PD-L2 in malignant
cells and various types of immune cells. This provides a more
comprehensive understanding of PD-1/ligand interactions between
tumor cells and the immune environment.
“Cancer therapy has been revolutionized by the development of IO
therapies, including checkpoint inhibitors and others. However,
response rates are variable and the development of more robust
assays is imperative. To our knowledge, Complete::IO™ is one of the
most comprehensive solutions for drug companies and physicians
seeking to optimize their novel treatment options, including mono-
and combination therapies” said Panna Sharma, CEO and President of
CGI. “The pharmaceutical industry has already recognized the merits
of applying this solution to biomarker studies as part of the
clinical development of novel cancer therapies, both as a valuable
tool for patient selection and for monitoring. We expect it to
become an integral component of additional IO studies to help
patients gain maximum benefit from immunotherapy options in the
treatment of cancer. The expansion of our Complete::IO™ panel is
key to our continued strategy to move beyond genomics to integrate
information about immune marker status, the tumor microenvironment
and cell surface biomarker expression in order to predict patient
responses.”
ABOUT CANCER GENETICS Cancer Genetics Inc. is a
leader in enabling precision medicine in oncology from bench to
bedside through the use of oncology biomarkers and molecular
testing. CGI is developing a global footprint with locations in the
US, India and China. We have established strong clinical research
collaborations with major cancer centers such as Memorial Sloan
Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of
Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services
that provide critical genomic and biomarker information. Its
state-of-the-art reference labs are CLIA-certified and
CAP-accredited in the US and have licensure from several states
including New York State.
For more information, please visit or follow CGI at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to Cancer Genetics’ strategic
focus and the future development, commercialization and outcomes
associated with its tests and testing services.
Any statements that are not historical fact (including, but not
limited to, statements that contain words such as “will,”
“believes,” “plans,” “anticipates,” “expects,” “estimates”) should
also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development
and/or commercialization of potential products, risks of
cancellation of customer contracts or discontinuance of trials,
risks that anticipated benefits from acquisitions will not be
realized, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights and other risks
discussed in the Cancer Genetics, Inc. Form 10-K for the year ended
December 31, 2016 and the Form 10-Q for the Quarter ended September
30, 2017 along with other filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Cancer Genetics, Inc. disclaims any obligation to
update these forward-looking statements.
Cancer Genetics ContactsMedia
RelationsKirsten Thomas
508-280-6592kthomas@theruthgroup.com
Investor RelationsLee Roth / Robert
Flamm646-536-7012 / 7017lroth@theruthgroup.com /
rflamm@theruthgroup.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Oct 2023 to Oct 2024